The mBos adds a 4th architectural axis to DEPLOY's surgical cluster: the autonomy-boundary (autonomous vs AI-augmented vs assistive). The cleared mBos is the AI-primary corner, the contrast to the surgeon-controlled orthopedic triangle (Mako/CORI/ROSA). Note the ownership symmetry: Zimmer Biomet now owns BOTH the surgeon-controlled ROSA and this autonomy line.
✔
The distinction is real and load-bearing: in the cleared mBos, the robotic arm executes the bone cut itself under AI control within a surgeon-approved CT plan and active supervision, where in Mako, CORI, and ROSA the surgeon makes the cut.
Price
No reviewed price is on record. We do not treat unverified analyst estimates as pricing data. There is no consumer price. The mBos is pre-commercial enterprise surgical equipment that has not sold any units; DEPLOY records zero price points.
Availability
Internal use only
The mBos is enterprise surgical equipment, not a consumer product, and it is pre-commercial: zero units sold. From Monogram Technologies (a Zimmer Biomet subsidiary since October 2025), commercialization alongside Zimmer Biomet implants is targeted for early 2027.
Real-world status
The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform and the autonomy-boundary case of DEPLOY's surgical cluster. Unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous: a robotic arm (built on a KUKA arm) executes the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. It pairs CT-based planning and predictive navigation with the robotic arm to execute cutting and insertion paths for Monogram's mPress press-fit implants. Several verified-vs-claimed cap-flags apply. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA). A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development (targeted around late 2027 or 2028); its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes.
⚠
Three verified-vs-claimed cap-flags: (1) FDA 510(k) was granted March 17, 2025, but the exact K-number could not be independently verified, and 'semi-autonomous' is sourced to Zimmer Biomet and trade press, not the FDA letter (Monogram's own PR said 'robotic-assisted TKA'); (2) the fully-autonomous, hands-free version is NOT FDA cleared and remains in development (~2027/2028); (3) its first fully-autonomous live-patient case (July 2025, Ahmedabad) was an India CDSCO trial, not US FDA, a single index case with no verified peer-reviewed outcomes.
⊘
There is no consumer price. The mBos is pre-commercial and has not sold any units, so DEPLOY records zero price points.
Surgical autonomy boundary: mBos vs ROSA vs Mako
Monogram mBos
Zimmer Biomet ROSA
Stryker Mako
Autonomy
Semi-autonomous (robot cuts)
🟢verified
Surgeon-controlled
🟢verified
Surgeon-controlled
🟢verified
State
Research (pre-commercial)
🟢verified
Commercial
🟢verified
Commercial
🟢verified
Maker
Monogram (ZB sub.)
🟢verified
Zimmer Biomet (ZBH)
🟢verified
Stryker (SYK)
🟢verified
Pricing
No consumer price
⊘absence
No consumer price
⊘absence
No consumer price
⊘absence
Sources: DEPLOY registry, Monogram / Zimmer Biomet, FDA / SEC
Frequently Asked Questions
Can I buy a Monogram mBos?
No⊘absence. The mBos is pre-commercial enterprise surgical equipment that has not sold any units; there is no consumer price.
Is the Monogram mBos autonomous?
The cleared mBos is semi-autonomous🟢verified: the robotic arm executes the bone cuts under AI control within a surgeon-approved CT plan and active surgeon supervision. A separate fully-autonomous, hands-free version is NOT FDA cleared🟢verified and remains in development.
Is the Monogram mBos FDA cleared?
It received FDA 510(k) clearance on March 17, 2025🟡stated, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own release said 'robotic-assisted TKA').
Is Monogram owned by Zimmer Biomet?
Yes, Zimmer Biomet completed the acquisition on October 7, 2025🟢verified (~$168M enterprise value plus contingent value rights). Zimmer Biomet now owns both the surgeon-controlled ROSA and this autonomy line; mBos commercialization is targeted for early 2027.
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.